Information Provided By:
Fly News Breaks for July 13, 2017
PODD, DXCM, ABT
Jul 13, 2017 | 12:39 EDT
BTIG analyst Sean Lavin sees Abbott's (ABT) deal to collaborate with Bigfoot Biomedical as a major validation of both Abbott's Libre technology and the platform of Bigfoot, which he views as a leader in the development of automated pancreases. For Dexcom (DXCM), this is a missed opportunity that could also be a sign that its grip on the CGM market may fade over time, but the company still has multiple shots with other pump systems and remains the market leader of standalone CGM, said Lavin. Insulet (PODD) is well underway in developing its Horizon AP platform and is unlikely to switch from Dexcom for its CGM, added Lavin, who keeps a Buy rating on Abbott and a Neutral rating on Dexcom.
News For ABT;DXCM;PODD From the Last 2 Days
There are no results for your query ABT;DXCM;PODD